Drug Pricing
Commentary
Europe Negotiates A Poor Vaccine Rollout
Several European countries just instituted another round of lockdowns amid a new wave of Covid-19 cases. This turn of events is sobering but puzzling. Europe seemed to have Covid-19 under control a few months ago, at least compared to the United States. What happened? The countries’ vaccination rates offer an explanation. Europe ...
Blog
Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation
The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for ...
Commentary
Drug Importation Programs Come At Too High a Cost
Lawmakers in Colorado are trying to open their state’s borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They’re still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs ...
Drug Pricing
Sanders Proposal Brings Medicare Closer To The Brink Of Collapse
President Joe Biden wants to lower Medicare’s eligibility age from 65 to 60. Now Sen. Bernie Sanders is intent on doing him one better. The Vermont socialist, the country’s leading promoter of single-payer health care, is pushing Democrats to open up Medicare to Americans as young as 55. “There are many millions of seniors ...
Commentary
Sanders Proposal Brings Medicare Closer To The Brink Of Collapse
President Joe Biden wants to lower Medicare’s eligibility age from 65 to 60. Now Sen. Bernie Sanders is intent on doing him one better. The Vermont socialist, the country’s leading promoter of single-payer health care, is pushing Democrats to open up Medicare to Americans as young as 55. “There are many millions of seniors ...
Drug Pricing
Wayne Winegarden – A Flawed Analysis on Valuing Medicines
The Institute for Clinical and Economic Review (ICER) promotes itself as “the nation’s drug pricing watchdog.” However, as documented in the first of a series of PRI reports, ICER’s cost-effectiveness analyses contain inappropriate methodologies and subjective judgments in determining the value of medicines. In this podcast, PRI senior fellow Wayne ...
Drug Pricing
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Commentary
Don’t Overreact to Rising Health Spending
U.S. healthcare spending has reached a new high, according to the latest federal data. The Centers for Medicare and Medicaid Services estimate national health expenditures reached $3.8 trillion in 2019, an increase of 4.6 percent over the previous year. That’s just under 18 percent of the national economy. It’s more ...
Commentary
Biden’s health care plans – this is what Americans can expect from Democrats
Last week, President Joe Biden signed executive orders that will re-open ObamaCare’s insurance exchanges from Feb. 15 through May 15 and direct federal agencies to re-examine some of the health care rules enacted by the Trump administration. There’s a limit to what Biden can accomplish by executive action. But with narrow control of Congress, there’s still plenty ...
Blog
It’s the Payment System
Effectively addressing the drug affordability problem requires an understanding of its causes. Toward this end, the rhetoric of Matt Eyles, the president and chief executive of America’s Health Insurance Plans (AHIP), is unhelpful. According to Eyles, “Americans are being hurt by out-of-control drug prices, which are set and fully controlled ...
Europe Negotiates A Poor Vaccine Rollout
Several European countries just instituted another round of lockdowns amid a new wave of Covid-19 cases. This turn of events is sobering but puzzling. Europe seemed to have Covid-19 under control a few months ago, at least compared to the United States. What happened? The countries’ vaccination rates offer an explanation. Europe ...
Here They Go Again: The Democratic Obsession with Drug Price Controls Will Harm Patients and Diminish Innovation
The U.S. House of Representatives is once again considering “The Lower Drug Costs Now Act”. It was a bad idea in the last Congress, and it is still bad policy today. If it becomes law, this Act (H.R. 3) empowers the federal government to negotiate prices on select drugs for ...
Drug Importation Programs Come At Too High a Cost
Lawmakers in Colorado are trying to open their state’s borders to prescription drugs from abroad. In 2019, they green-lit imports from Canada. They’re still working on a plan to implement that policy that can garner federal approval. Then last week, legislators approved a bill that would allow Coloradans to import prescription drugs ...
Sanders Proposal Brings Medicare Closer To The Brink Of Collapse
President Joe Biden wants to lower Medicare’s eligibility age from 65 to 60. Now Sen. Bernie Sanders is intent on doing him one better. The Vermont socialist, the country’s leading promoter of single-payer health care, is pushing Democrats to open up Medicare to Americans as young as 55. “There are many millions of seniors ...
Sanders Proposal Brings Medicare Closer To The Brink Of Collapse
President Joe Biden wants to lower Medicare’s eligibility age from 65 to 60. Now Sen. Bernie Sanders is intent on doing him one better. The Vermont socialist, the country’s leading promoter of single-payer health care, is pushing Democrats to open up Medicare to Americans as young as 55. “There are many millions of seniors ...
Wayne Winegarden – A Flawed Analysis on Valuing Medicines
The Institute for Clinical and Economic Review (ICER) promotes itself as “the nation’s drug pricing watchdog.” However, as documented in the first of a series of PRI reports, ICER’s cost-effectiveness analyses contain inappropriate methodologies and subjective judgments in determining the value of medicines. In this podcast, PRI senior fellow Wayne ...
ISSUE BRIEF: ICER Analyses Are Flawed, Undervalue Life-Saving Medicines, and Are Biased Toward Price Controls
A commonly-used analysis to determine a medicine’s value is based on flawed methodologies that would diminish innovation and access, finds a new report released today by the nonpartisan Center for Medical Economics and Innovation at the Pacific Research Institute. “Cost effectiveness reports may provide precise estimates, but there is no ...
Don’t Overreact to Rising Health Spending
U.S. healthcare spending has reached a new high, according to the latest federal data. The Centers for Medicare and Medicaid Services estimate national health expenditures reached $3.8 trillion in 2019, an increase of 4.6 percent over the previous year. That’s just under 18 percent of the national economy. It’s more ...
Biden’s health care plans – this is what Americans can expect from Democrats
Last week, President Joe Biden signed executive orders that will re-open ObamaCare’s insurance exchanges from Feb. 15 through May 15 and direct federal agencies to re-examine some of the health care rules enacted by the Trump administration. There’s a limit to what Biden can accomplish by executive action. But with narrow control of Congress, there’s still plenty ...
It’s the Payment System
Effectively addressing the drug affordability problem requires an understanding of its causes. Toward this end, the rhetoric of Matt Eyles, the president and chief executive of America’s Health Insurance Plans (AHIP), is unhelpful. According to Eyles, “Americans are being hurt by out-of-control drug prices, which are set and fully controlled ...
